Abstract:161 Objectives: T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types. Tumor infiltrating T cells express the high affinity interleukin-2 (IL2) receptor (CD25) on their surface. These T cells could therefore be visualized by molecular imaging with a radiolabeled IL2 for this receptor. For this purpose, [18F]FB-IL2 was designed as a PET imaging probe for T cell imaging, but strictly limited by its low target-to-background ratios and toxicity, which was resulted from direct binding of IL-2 to αβγ IL-2Rs on lung endothelial cells. Interaction of IL-2 with lung endothelial cells can be abrogated by blocking IL2 and IL-2Rα interaction. Here we developed a novel T cell imaging probe based on mutant Interleukin-2 (mIL2), which reduced binding to IL-2Rα and increased binding affinity for IL-2Rβ and may lead to higher target-to-background ratios and less toxicity in vivo than IL2. Methods: Mutant Interleukin-2 was expressed in Sf9 cells and purified by Ni-NTA, then concentrated using spin concentrators and purified with an FPLC Superdex 75 sizing column. The bioactivity of purified mIL2 was detected with the CTLL2 cells which were dependent upon IL-2 for growth. IL2/IL-2Rα interaction was detected by ELISA. Then, mIL2 was radiolabeled with 99mTc-HYNIC-GGGGK conjugated to the LPETG tag through Sortase A. The pharmacokinetic data of 99mTc-HYNIC-mIL2 was obtained by ex vivo biodistribution experiments. Finally, the tumor infiltrating T cells detecting capability of 99mTc-HYNIC-mIL2 in MC38 subcutaneous tumor-bearing mice was evaluated by in vivo NanoScan SPECT/CT imaging. Results: mIL2 showed bioactivity with CTLL2 cells whereas lower CD25 binding compared with IL2. The 99mTc-labeling procedure was done within 2 h, with a yield of 70%. The radiochemical purity was greater than 98%. As shown in figure 1, the tumor-infiltrating T cells located in the MC38 tumor margin was clearly visualized by 99mTc-HYNIC-mIL2 NanoScan SPECT/CT imaging with low background except relatively high kidney uptake at all detected time points (0.5 and 2 h p.i.). Specificity of 99mTc-HYNIC-mIL2 to T cells was demonstrated by competitive blocking of tumor uptake with excess mIL2. Biodistribution results showed that the tumor uptake of 99mTc-HYNIC-mIL2 at 0.5 and 2 h p.i. was 2.59 ± 0.37 %ID/g and 2.19 ± 0.16 %ID/g, respectively. Conclusions: 99mTc-HYNIC-mIL2 is a promising SPECT radiotracer for the noninvasive imaging of tumor infiltrating T cells, which showed high target-to-background ratios. This novel tracer possesses enormous potential for evaluating and guiding immunotherapy in clinical practice, and its further investigation is still in progress.

An Optimized LC-MS/MS Method for Determination of HYNIC-3PRGD2, a New Promising Imaging Agent for Tumor Targeting, in Rat Plasma and Its Application.

Simultaneous quantification of pirarubicin, doxorubicin, cyclophosphamide, and vincristine in human plasma of patients with non-Hodgkin's lymphoma by LC-MS/MS method.

Simultaneous quantification of icaritin and its novel 3-methylcarbamate prodrug in rat plasma using HPLC-MS/MS and its application to pharmacokinetic study

A High-Sensitivity Lc-Ms/Ms Method for the Determination of 4-Methyl-piperazine-1-carbodithioc Acid 3-Cyano-3, 3-Diphenylpropyl Ester Hydrochloride in Rat Plasma and Its Application to A Pharmacokinetics Study

99Mtc-Labeling and Evaluation of a HYNIC Modified Small-Molecular Inhibitor of Prostate-Specific Membrane Antigen.

Improving Tumor-Targeting Capability and Pharmacokinetics of 99Mtc-Labeled Cyclic RGD Dimers with PEG4 Linkers

Application of 99mTc-Labeled WL12 Peptides as a Tumor PD-L1-Targeted SPECT Imaging Agent: Kit Formulation, Preclinical Evaluation, and Study on the Influence of Coligands

Preliminary study of molecular imaging of human hepatocellular carcinoma xenograft with Gd-based MR probe containing arginine-glycine-aspartic acid chelate

A Validated UHPLC-MS/MS Method for Determination of TQ-B3203 in Human Plasma and Its Application to a Pharmacokinetic Study in Chinese Patients with Advanced Solid Tumor

Imaging of 99Tcm-Labeled New Cyclic RGDfK Dimer in Nude Mice Bearing U87MG Human Glioma Xenografts

Liquid Chromatography ICP-MS to Assess the Stability of 175Lu- and natGa-Based Tumor-Targeting Agents towards the Development of 177Lu- and 68Ga-Labeled Radiopharmaceuticals

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

Preliminary Study of Molecular Imaging of Human Hepatoceilular Carcinoma Xenoggaft with Gd-based MR Probe Containiug Arginine-Glycine-aspartic Acid Chelate

Gd-EDDA/HYNIC-RGD As an MR Molecular Probe Imaging Integrin Alphanubeta3 Receptor-Expressed Tumor-Mr Molecular Imaging of Angiogenesis.

A Novel Integrinαvβ3-Targeted Isodgr Probe for SPECT/CT Imaging of Glioma

Design and Synthesis of 111In-Ccpm-rgd Nanoparticles for Dual-modality Molecular Imaging

Determination of a novel anticancer AMPK activator hernandezine in rat plasma and tissues with a validated UHPLC–MS/MS method: Application to pharmacokinetics and tissue distribution study

Evaluation of a 99Mtc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin Αvβ3-Positive Breast Cancer

99Mtc-Labeled Mutant Interleukin-2 As a Promising SPECT Probe for in Vivo Imaging of Tumor-Infiltrating T Cells

Quantification of CPT13 in rat plasma using LC–MS/MS for a pharmacokinetic study

Determination of biodistribution of 99mTc-3PRGD2 in mice bearing the lung carcinoma xenograft byγcounter